Phase II Trial of Pegylated Liposomal Doxorubicin-Cyclophosphamide Combination as First-Line Chemotherapy in Older Metastatic Breast Cancer Patients

Oncology ◽  
2007 ◽  
Vol 73 (3-4) ◽  
pp. 210-214 ◽  
Author(s):  
J.E. Kurtz ◽  
F. Rousseau ◽  
N. Meyer ◽  
T. Delozier ◽  
D. Serin ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Cancer Patients ◽  
Liposomal Doxorubicin ◽  
Phase Ii Trial ◽  
Metastatic Breast ◽  
Pegylated Liposomal Doxorubicin ◽  
Breast Cancer Patients ◽  
First Line ◽  
Line Chemotherapy

Phase II trial of pegylated liposomal doxorubicin-cyclophosphamide combination as first-line chemotherapy in elderly metastatic breast cancer patients

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 19565-19565 ◽  
Author(s):  
P. R. Dufour ◽  
F. Rousseau ◽  
N. Meyer ◽  
T. Delozier ◽  
D. Serin ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Endocrine Therapy ◽  
Liposomal Doxorubicin ◽  
Phase Ii Trial ◽  
Metastatic Breast ◽  
Pegylated Liposomal Doxorubicin ◽  
First Line ◽  
Grade 3 ◽  
Line Chemotherapy

19565 Background: Although the majority of metastatic breast cancer (MBC) patients (pts) responds to endocrine therapy, treatment failure is a concern, as well as front-line therapy for pts with ER/PR negative disease.The combination of anthracyclines (A) and cyclophosphamide (C) is active in younger pts, but cardiac toxicity of A in elderly MBC pts has to be considered. Pegylated liposomal doxorubicin (PLD) (Caelyx®) is active in MBC and has much less cardiotoxicity than A, and we present the preliminary data of the PLD/C in elderly MBC pts. Methods: This was a multicentric phase II trial. Inclusion criteria included: pts aged between 65 and 75, histologically proven measurable MBC, ECOG PS 0–1, LVEF = 50%, first-line chemotherapy for MBC. Prior adjuvant chemotherapy was allowed if stopped for = 6 or 12 months without and with anthracyclines, respectively. Endocrine therapy either in the adjuvant or metastatic setting had to be stopped for = 1 month. All pts gave a written informed consent. The treatment schedule was : PLD 40mg/m2 and C 500mg/m2 d1 every 4 weeks. Efficacy as well as response duration and tolerance were the primary and secondary end-points, respectively. Results: 35 patients were enrolled (Median age 71.3, range 65.6–75.9). A total of 166 cycles have been administered. The median number of cycles was 6 (range 1–9). No toxic death was reported, one patient died of diabetes mellitus decompensation. No congestive heart failure or decrease in LVEF was reported, although 1 pt experience grade 3 dyspnea and stopped treatment. Other (gr3–4) NCI-CTC toxicity included: neutropenia in 7 (gr3) and 3 (gr4) pts; gr3 mucositis (4). No febrile neutropenia was reported. Grade 3 hand-foot syndrome occurred in 1 pt, whereas treatment was stopped due to a generalized rash in 1 pt. An objective response (CR + PR) was achieved in 10 (28,6%) pts (1 CR and 8 PR), and a disease control in 24 (68.6%) with a progression free survival of 8.8 months and a median survival of 20.4 months Conclusions: The LPD-C combination is active in elderly MBC pts, with an acceptable toxicity profile. No significant financial relationships to disclose.

Carboplatin and docetaxel as first-line chemotherapy in metastatic breast cancer patients. Preliminary results

2005 ◽  
Vol 23 (16_suppl) ◽  
pp. 862-862
Author(s):  
M. E. Vassilomanolakis ◽  
G. Koumakis ◽  
V. Barbounis ◽  
S. Demiris ◽  
C. Panopoulos ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Cancer Patients ◽  
Metastatic Breast ◽  
Breast Cancer Patients ◽  
First Line ◽  
Preliminary Results ◽  
Line Chemotherapy

First‐Line Chemotherapy for HER‐2–Negative Metastatic Breast Cancer Patients Who Received Anthracyclines as Adjuvant Treatment

2007 ◽  
Vol 12 (11) ◽  
pp. 1288-1298 ◽  
Author(s):  
Alessandro Morabito ◽  
Maria Carmela Piccirillo ◽  
Katia Monaco ◽  
Carmen Pacilio ◽  
Francesco Nuzzo ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Cancer Patients ◽  
Adjuvant Treatment ◽  
Metastatic Breast ◽  
Breast Cancer Patients ◽  
First Line ◽  
Her 2 ◽  
Line Chemotherapy
Sign in / Sign up

Export Citation Format

Share Document